OurMind

PUBLIC

Name	OurMind
Tagline	AI platform that automates clinical documentation and workflows for healthcare professionals.
Headquarters	Amsterdam, Netherlands
Founded	2024
Stage	Seed
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$2,420,000)

Links

PUBLIC

• Website: https://www.ourmind.ai/
• LinkedIn: https://www.linkedin.com/company/ourmind-ai/

Executive Summary

PUBLIC OurMind is an Amsterdam-based healthtech startup building an AI platform to automate clinical documentation, a wedge into a market defined by clinician burnout and administrative inefficiency [AIPressroom, June 2026]. Founded in 2024 by a group including a former orthopedic surgeon with a prior exit, the company has secured €2.1 million in seed capital to validate its core proposition: that a medical scribe tailored to hospital-specific templates and integrated into existing EHR workflows can capture meaningful adoption [AI Funding, June 2026].

The founding team provides a credible foundation, led by Paul Koning, MD, whose previous venture, Prisma Network, was acquired by the European healthtech giant Doctolib [PERPLEXITY SONAR PRO BRIEF]. This domain-specific founder-market fit is paired with an AI engineering co-founder, Fredrik Gustafsson, suggesting a balance of clinical insight and technical execution [PERPLEXITY SONAR PRO BRIEF]. The business model is a vertical SaaS subscription targeting healthcare organizations, with initial traction reported at over 300 general practices and 14 hospitals, though specific customer logos remain undisclosed [4impact, June 2026].

Over the next 12-18 months, the key indicators to monitor will be the expansion of these early deployments into larger, named hospital systems, the evolution of the platform beyond note transcription into broader workflow automation, and the company's ability to convert its reported usage into sustained, high-value contracts. The initial funding provides a runway to pursue these goals, but the competitive landscape is dense with well-funded incumbents, making execution on integration depth and clinical accuracy the primary determinants of scale.

Data Accuracy: GREEN -- Key claims on funding, team background, and product positioning are corroborated by multiple independent sources including Caplight, AIPressroom, and AI Funding.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$2,420,000)

Company Overview

PUBLIC

OurMind emerged in 2024 from a founding team of clinicians and engineers in Amsterdam, focused on a specific and growing problem in European healthcare. The company's origin is tied directly to the professional experience of co-founder Paul Koning, MD, a former orthopedic surgeon who had previously founded and sold a healthtech company [PERPLEXITY SONAR PRO BRIEF]. The founding group, which includes Marco Ferraz, Fredrik Gustafsson, and Renan Sales Barros, started with the stated aim of improving healthcare accessibility and outcomes worldwide using generative AI [Sabine Janssen - Huisartsenpraktijk t Zand | LinkedIn, retrieved 2026]. Their initial target was the administrative burden on clinicians, a well-documented source of burnout [Djoeri Timessen - Xapo Bank | LinkedIn, retrieved 2026].

Key milestones followed a rapid, execution-oriented path. The company developed its core AI documentation platform and secured its first institutional capital in June 2026, a €2.1 million (approximately $2.4 million) early funding round led by 4impact capital [AIPressroom, June 2026] [Caplight, June 2026]. Concurrent with the funding, the company announced its platform was already in use by more than 300 general practices and 14 hospitals, indicating a deployment-first approach to gaining market traction [4impact, June 2026]. The company also achieved ISO 27001 and NEN 7510 certifications for information security, a critical step for operating in the healthcare sector [AI World, June 2026].

Data Accuracy: GREEN -- Founding details and funding round confirmed by multiple independent sources. Customer deployment figures cited by a lead investor.

Product and Technology

MIXED OurMind’s core proposition is a generative AI platform designed to function as a digital colleague for healthcare professionals, automating the administrative tasks that contribute to clinician burnout. The platform centers on two primary modules: OurMind Notes, which transcribes physician-patient conversations into structured clinical reports, and OurMind Assistant, which handles letters, referrals, and answers to protocol questions [OurMind]. The company emphasizes deep integration with existing electronic health record (EHR) systems, formatting documentation to hospital-specific templates, which suggests a product built for compliance and workflow fit over generic transcription [OurMind].

Technical and operational details are framed around security and scalability. The platform supports conversations in over 68 languages and processes audio with a stated focus on data privacy: audio is deleted immediately after processing and transcripts are automatically removed after 72 hours [OurMind] [AI World, June 2026]. Public certifications include ISO 27001 and the Dutch healthcare-specific NEN 7510 standard, providing a tangible trust signal for European healthcare buyers [AI World, June 2026]. The go-to-market approach includes a 30-day free trial, and the company has announced plans to soon offer templates for psychosocial and mental health nurse practitioner consultations [OurMind].

Data Accuracy: GREEN -- Product claims are confirmed by the company website and independent press coverage. Security certifications are specifically cited in a June 2026 news article.

Market Research

PUBLIC The market for AI-powered clinical documentation is expanding not merely as a productivity tool but as a structural response to a healthcare workforce crisis. This demand is driven by a persistent administrative burden that contributes to clinician burnout, a problem well-documented in industry research and now being addressed by a wave of venture-backed solutions.

OurMind operates within the specific segment of AI medical scribes and clinical workflow automation. While the company has not publicly disclosed its own market sizing, the broader category is frequently analyzed. For context, the global AI in healthcare market was valued at $15.1 billion in 2022 and is projected to reach $187.95 billion by 2030, growing at a compound annual growth rate (CAGR) of 37% from 2023 to 2030 [Grand View Research, 2023]. The AI clinical documentation segment, a key sub-category, is often cited as one of the fastest-growing applications within this market due to its direct impact on operational costs and clinician satisfaction.

Key demand drivers for this segment are clear from third-party analysis. The primary tailwind is the overwhelming administrative load on healthcare providers. Studies consistently show physicians spend nearly two hours on administrative work for every one hour of direct patient care, a ratio that fuels high rates of professional burnout [Annals of Internal Medicine, 2016]. This creates a direct economic incentive for health systems to adopt automation tools. Secondary drivers include the ongoing digitization of health records, which provides the necessary infrastructure for AI integration, and the increasing comfort with ambient listening technologies in clinical settings, lowering adoption barriers.

Adjacent and substitute markets influence the competitive dynamics. The core substitute remains manual documentation or traditional transcription services, which are labor-intensive and costly. Adjacent markets include broader healthcare workflow software, electronic health record (EHR) systems themselves, and patient engagement platforms. Regulatory forces are a critical consideration, particularly in Europe where OurMind is based. Compliance with data protection regulations like the GDPR and industry-specific standards like ISO 27001 and NEN 7510 (which OurMind cites) is not optional but a fundamental cost of entry and a significant barrier for less specialized entrants [AI World, June 2026].

Metric	Value
Global AI in Healthcare Market (2022)	15.1 $B
Projected Market (2030)	187.95 $B
CAGR (2023-2030)	37 %

The projected growth rate underscores the scale of the opportunity, but the 37% CAGR figure, while indicative of sector momentum, should be treated as an analogous market benchmark rather than a precise forecast for the clinical documentation niche. The high growth expectation reflects significant investor confidence in AI's ability to address systemic healthcare inefficiencies.

Data Accuracy: YELLOW -- Market sizing figures are from a third-party analyst report for the broader AI in healthcare sector, not specific to clinical documentation. Demand drivers are supported by independent medical journals and industry analysis.

Competitive Landscape

MIXED OurMind enters a crowded field of AI-powered clinical documentation assistants, but its early positioning suggests a deliberate focus on deep, localized integration within the European healthcare system rather than competing head-on with the largest U.S.-based generalists.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
OurMind	AI platform automating clinical documentation and workflows for European healthcare providers.	Seed, ~$2.4M (June 2026)	ISO 27001/NEN 7510 certified; focus on hospital-specific templates and EHR integration in the Netherlands.	[4impact, June 2026]
Abridge	AI-powered clinical documentation and conversation capture, integrated with major U.S. EHRs.	Series C, $150M+	Strong partnerships with Epic and other large U.S. health systems; FDA-cleared for certain use cases.	[Crunchbase]
DAX Copilot (Nuance)	Ambient clinical intelligence integrated into Microsoft's ecosystem for healthcare.	Product of Microsoft (via Nuance acquisition)	Deep integration with Microsoft 365, Teams, and Azure; enterprise-scale distribution through existing Nuance/Microsoft channels.	[Microsoft]
DeepScribe	AI medical scribe focused on capturing the natural patient visit.	Series A, $30M+	Emphasis on ambient, non-intrusive capture and specialty-specific workflows.	[Crunchbase]
Suki	Voice-enabled digital assistant for clinicians, specializing in EHR data entry.	Series C, $55M+	Long-standing focus on voice as primary interface; partnerships with health systems like AdventHealth.	[Crunchbase]

A competitive map of this sector reveals distinct layers. At the top are the scaled incumbents and ecosystem players, such as Microsoft's DAX Copilot, which leverages an existing massive installed base of healthcare enterprise customers. The next tier consists of well-funded, U.S.-centric pure-plays like Abridge and Suki, which have secured significant capital to pursue broad adoption across American health systems, often through direct EHR partnerships. Adjacent substitutes include traditional medical transcription services and the manual data entry they aim to replace, which represent the entrenched, non-automated workflow. OurMind currently operates in a more focused challenger tier, targeting a specific geographic and regulatory niche.

The company's most defensible edge today is its combination of founder-led domain expertise and early certification for the European market. Founder Paul Koning's background as a surgeon and his prior exit to Doctolib provides credibility and network access within European healthtech that a generic AI team would lack [PERPLEXITY SONAR PRO BRIEF]. Furthermore, achieving ISO 27001 and the Dutch NEN 7510 certification for information security in healthcare is a non-trivial compliance hurdle that serves as a near-term moat against less specialized entrants [AI World, June 2026]. This edge is durable if the company continues to deepen integrations with local EHRs and practice management systems, but it is perishable if larger U.S. competitors decide to make a concerted push into Europe and undertake the same certification process.

OurMind's primary exposure lies in its limited scale and capital runway relative to its named competitors. While it serves over 300 general practices and 14 hospitals [4impact, June 2026], this footprint is regional. A competitor like Abridge, with over $150 million in funding, can afford to invest heavily in model accuracy, sales teams, and global compliance, potentially outpacing OurMind's organic expansion. Furthermore, the company does not yet own a proprietary distribution channel; its growth is contingent on direct sales and partnerships in a market where large EHR vendors hold significant sway over clinician access.

The most plausible 18-month scenario is one of continued regional consolidation rather than winner-take-all. The "winner" in the Dutch and adjacent markets will be the company that most seamlessly becomes an invisible layer within the daily workflow of GPs and hospitalists, likely through an exclusive or preferred partnership with a dominant local healthcare IT provider. OurMind is positioned for this, but execution risk is high. The "loser" in this timeframe would be any undifferentiated, generic transcription tool that fails to meet stringent European data governance standards or to understand localized clinical workflows, as regulatory scrutiny increases.

Data Accuracy: YELLOW -- Competitor funding and positioning are widely reported, but specific differentiation claims for OurMind are based on company materials and a single investor press release.

Opportunity

PUBLIC

The opportunity for OurMind is to become the dominant AI-native layer for clinical workflow automation in European healthcare, a role that could scale to a multi-billion dollar enterprise if it captures even a modest share of a market defined by severe administrative strain and a shortage of clinical personnel.

The headline opportunity is to evolve from a medical scribe into the default clinical operating system for primary and secondary care across Europe. The evidence that makes this outcome reachable, rather than purely aspirational, lies in the team's prior exit to a major healthtech platform, the immediate traction within a tightly regulated market, and the product's design as an integrated workflow hub. Paul Koning's prior company, Prisma Network, was acquired by Doctolib, a platform used by hundreds of thousands of healthcare professionals [PERPLEXITY SONAR PRO BRIEF]. This exit demonstrates not only founder credibility but also a proven ability to build and sell into the complex European healthcare ecosystem. Furthermore, the company's reported deployment in over 300 general practices and 14 hospitals, achieved within two years of founding, indicates an early wedge that goes beyond pilot projects [4impact, June 2026]. The product's stated integration into EHR systems and formatting to hospital-specific templates suggests a path beyond point-solution transcription toward becoming an essential, sticky layer of the clinical tech stack [PERPLEXITY SONAR PRO BRIEF].

Growth from this wedge could follow several concrete, high-scale paths. The table below outlines two primary scenarios.

Scenario	What happens	Catalyst	Why it's plausible
National Standard in the Netherlands	OurMind becomes the de facto AI documentation tool for Dutch primary care and a majority of regional hospitals, embedded in procurement frameworks.	A partnership with a major Dutch hospital group or insurer to co-develop and roll out the platform nationally.	The company is already ISO 27001 and NEN 7510 certified, meeting the stringent Dutch healthcare data security standards required for large contracts [AI World, June 2026]. Early traction with 300+ practices provides a reference base.
Platform Expansion into Chronic Care Management	The product expands from visit documentation to managing longitudinal patient journeys for conditions like diabetes or mental health, becoming a reimbursable care coordination tool.	Launch of dedicated modules for "psychosocial consultations" and mental health nurse practitioner workflows, as indicated on the company's website [OurMind].	The administrative burden is particularly high in chronic and mental health care. The company's planned template development shows intent to move beyond general documentation into specialized, high-value workflows.

Compounding for OurMind would manifest as a data and workflow integration moat. Each new hospital deployment generates proprietary templates and integration logic for that institution's specific EHR and documentation protocols. This creates significant switching costs. Furthermore, as the platform handles more consultations, the underlying AI models could be refined on a diverse, European-accented medical corpus, potentially improving accuracy for local dialects and medical terminology in a way generic, US-focused competitors cannot easily match. The company's emphasis on immediate audio deletion and 72-hour transcript retention addresses a core privacy concern, which could become a regulatory and trust advantage as data governance rules tighten [AI World, June 2026]. This trust layer, combined with deep EHR integration, forms the beginning of a lock-in effect where replacing OurMind would require retraining staff and rebuilding custom integrations.

The size of the win can be framed by looking at a credible comparable. Suki, a US-based AI clinical assistant and scribe company, reportedly achieved a post-money valuation of approximately $400 million during its Series C round in 2021 [Forbes, October 2021]. While market conditions have shifted, this provides a benchmark for a specialized, venture-scale player in the clinical documentation automation space. If OurMind executes on the "National Standard" scenario and captures a leading position in the Dutch market,a country with a highly digitized, centralized healthcare system,it could reasonably command a valuation in the high hundreds of millions as a strategic asset for a larger healthtech player or as a standalone public company in Europe. This represents a scenario, not a forecast, but it illustrates the magnitude of the opportunity given the company's starting position and the acute problem it is solving.

Data Accuracy: YELLOW -- The core traction metrics (300+ practices, 14 hospitals) are cited by an investor. The valuation comparable is from a dated source. Growth scenarios are plausible extrapolations based on public product roadmaps and certifications.

Sources

PUBLIC

1. [AIPressroom, June 2026] OurMind Raises €2.1M to Streamline Healthcare Admin | https://aipressroom.com/ourmind-2m-healthcare-ai/

2. [AI Funding, June 2026] OurMind Funding & Valuation | https://aifunding.dk/company/ourmind

3. [AI World, June 2026] OurMind Achieves Key Security Certifications | https://aiworld.com/ourmind-security-certifications/

4. [Annals of Internal Medicine, 2016] Allocation of Physician Time in Ambulatory Practice | https://www.acpjournals.org/doi/10.7326/M16-0961

5. [Caplight, June 2026] OurMind | Valuation, Funding Rounds & Stock Price | https://www.caplight.com/company/

6. [Crunchbase] Abridge Company Profile | https://www.crunchbase.com/organization/abridge

7. [Crunchbase] DeepScribe Company Profile | https://www.crunchbase.com/organization/deepscribe

8. [Crunchbase] Suki Company Profile | https://www.crunchbase.com/organization/suki

9. [Djoeri Timessen - Xapo Bank | LinkedIn, retrieved 2026] LinkedIn Post on OurMind's Mission | https://www.linkedin.com/in/djoeri/

10. [Forbes, October 2021] Suki Raises $55 Million to Expand Its AI Assistant for Doctors | https://www.forbes.com/sites/rebeccaszkutak/2021/10/20/suki-raises-55-million-to-expand-its-ai-assistant-for-doctors/

11. [Grand View Research, 2023] Artificial Intelligence In Healthcare Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market

12. [Microsoft] DAX Copilot Product Overview | https://www.microsoft.com/en-us/industry/health/nuance-dax-copilot

13. [OurMind] OurMind Product and Company Website | https://www.ourmind.ai/

14. [PERPLEXITY SONAR PRO BRIEF] OurMind Company Briefing | https://www.perplexity.ai/

15. [Sabine Janssen - Huisartsenpraktijk t Zand | LinkedIn, retrieved 2026] LinkedIn Post on OurMind's Founding | https://www.linkedin.com/in/sabine-janssen-58b782a9/

16. [4impact, June 2026] 4impact Capital Announces Investment in OurMind | https://4impact.capital/news/ourmind-investment